Share this article

GlaxoSmithKline (GSK) has announced plans to invest $100m to support long-term vaccine manufacturing capabilities at its facility in Hamilton, Montana, US.

The UK-based pharmaceutical company intends to improve the production of the main components of its adjuvant system, which is used in many of its vaccines, including products used to prevent malaria and shingles.

GSK’s adjuvant systems are designed to elicit a strong immune response. The Hamilton site is currently engaged in manufacturing the components of this technology and the investment will further expand these capabilities.

“We will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix.”

GSK US Pharmaceuticals president Jack Bailey said: “For more than a decade, our Hamilton facility has supported GSK’s adjuvant system development programme.

“By expanding the adjuvant system production capabilities in Hamilton, we will continue to deliver long-term and sustainable supply for key vaccines, including Shingrix.”

GSK’s Shingrix vaccine received US Food and Drug Administration (FDA) approval in October 2017 and has been in short supply after rapid uptake last year.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

With a portfolio of in excess of 40 vaccines, GSK provides more than two million doses each day to patients across 160 countries. The company’s vaccines help address 22 conditions, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. It has a pipeline of 14 vaccine candidates currently in development.

In 2017, the vaccines business accounted for 17% of GSK’s total turnover, generating $6.7bn in sales.

Hamilton is one of the nine manufacturing sites GSK has in the US. Its expansion will create temporary construction and contracting jobs, along with permanent GSK positions, including scientists, engineers and manufacturing and quality professionals over the next few years.